World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
144
Citations
71526
World Ranking
1452
National Ranking
848

Overview

Teru Hideshima is affiliated with Harvard University in the United States and has focused their research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans multiple areas with notable concentration in molecular biology, hematology, oncology, immunology, and pathology and forensic medicine as subfields of study.

Their research topics include the investigation of multiple myeloma research and treatments, protein degradation and inhibitors, peptidase inhibition and analysis, ubiquitin and proteasome pathways, cancer mechanisms and therapy, immunotherapy and immune responses, and immune cell function and interaction.

Frequent publication venues for Hideshima's work include Blood, Cancer Research, Clinical Lymphoma Myeloma & Leukemia, Leukemia, and Blood Cancer Journal.

Among their recent scientific papers are:

  • Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation, 2021, Blood Cancer Discovery
  • The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications, 2020, Blood
  • Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma, 2021, Leukemia
  • Signaling Pathway Mediating Myeloma Cell Growth and Survival, 2021, Cancers
  • Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways, 2020, Leukemia

Hideshima collaborates frequently with researchers such as Kenneth C. Anderson, Yu-Tzu Tai, Nikhil C. Munshi, Kenneth Wen, and Annamaria Gullà. These partnerships are reflected in the number of coauthored publications and contribute to the breadth of their research scope.

Best Publications

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

    Teru Hideshima;Paul Richardson;Dharminder Chauhan;Vito J. Palombella

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • NF-κB as a Therapeutic Target in Multiple Myeloma *

    Teru Hideshima;Dharminder Chauhan;Paul Richardson;Constantine Mitsiades

  • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

    Teru Hideshima;Constantine Mitsiades;Giovanni Tonon;Paul G. Richardson

  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

    Paul G. Richardson;Robert L. Schlossman;Robert L. Schlossman;Edie Weller;Edie Weller;Teru Hideshima;Teru Hideshima

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Molecular sequelae of proteasome inhibition in human multiple myeloma cells

    Nicholas Mitsiades;Constantine S. Mitsiades;Vassiliki Poulaki;Dharminder Chauhan

  • The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

    Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Vassiliki Poulaki

  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

    D Gupta;S P Treon;Y Shima;T Hideshima

  • Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

    Nicholas Mitsiades;Constantine S. Mitsiades;Vassiliki Poulaki;Dharminder Chauhan

  • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

    Dharminder Chauhan;Laurence Catley;Guilan Li;Klaus Podar

  • Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

    S. Vincent Rajkumar;Paul G. Richardson;Teru Hideshima;Kenneth C. Anderson

  • Advances in biology of multiple myeloma: clinical applications

    Teru Hideshima;P. Leif Bergsagel;W. Michael Kuehl;Kenneth C. Anderson

  • Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

    Constantine S Mitsiades;Nicholas S Mitsiades;Nicholas S Mitsiades;Ciaran J McMullan;Vassiliki Poulaki;Vassiliki Poulaki

  • Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

    Teru Hideshima;Constantine Mitsiades;Masaharu Akiyama;Toshiaki Hayashi

  • Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

    Teru Hideshima;James E. Bradner;Jason Wong;Dharminder Chauhan

  • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

    Constantine S. Mitsiades;Nicholas S. Mitsiades;Ciaran J. McMullan;Vassiliki Poulaki

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

Frequent Co-Authors

Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Noopur Raje
Noopur Raje Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Klaus Podar
Klaus Podar Karl Landsteiner University of Health Sciences
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Robert L. Schlossman
Robert L. Schlossman Harvard University
Irene M. Ghobrial
Irene M. Ghobrial Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA isn’t limited to traditional medical school routes. Many students consider alternative degrees and certifications that provide entry into healthcare fields with more flexible study options and cost-effective pathways.

For those seeking a quick start, how much is medical billing and coding school is a common question. Medical billing and coding programs are popular because they offer fast, online training at lower costs, leading to administrative roles in clinics and hospitals.

Nursing remains one of the most in-demand professions. If you’re interested in advanced practice, you might explore the cheapest online np programs. These programs prepare registered nurses to become nurse practitioners, a high-responsibility healthcare role with strong job prospects.

For foundational nursing education, there are many affordable nursing programs available online, making it easier to earn your degree on a budget. Ambitious professionals may also consider online phd nursing programs to open doors in research, academia, or leadership.

These online degree and certificate pathways offer flexible, affordable options for entering and advancing in the healthcare field—helping you achieve your career goals beyond traditional medical school.

Best Scientists Citing Teru Hideshima

Trending Scientists

Recently Published Articles